Leucid Bio, a spin out company from King’s College London is focused on the development of new treatments for cancer. The company is developing a pioneering technology utilising engineered T cells.
VIEW WEBSITE >>
Location: United Kingdom, England, London
Total raised: $15.87M
Investors 1
| Date | Name | Website |
| - | Epidarex C... | epidarex.c... |
Funding Rounds 1
| Date | Series | Amount | Investors |
| 22.10.2021 | Series A | $15.87M | - |
Mentions in press and media 4
| Date | Title | Description | Source |
| 27.10.2021 | London-based biotech Leucid Bio raises £11.5M funding for ha... | London-based biotech Leucid Bio raises £11.5M funding for hard-to-treat | vulpesinve... |
| 22.10.2021 | Leucid Bio Raises £11.5M in Series A Funding | Leucid Bio, a London UK-based biotech company, raised £11.5M in series A funding. The round was led... | finsmes.co... |
| 22.10.2021 | Is former WeWork CEO Adam Neumann preparing his second act? | This is the web version of Term Sheet, a daily newsletter on the biggest deals and dealmakers. Sign ... | fortune.co... |
| 21.10.2021 | Leucid Bio Raises £11.5Million In Series A Financing To Deve... | Leucid Bio a biotech company pioneering next-generation cell therapies for hard-to-treat cancers, to... | aithority.... |